Data Presented at 2022 International Stroke Congress Suggests Role for Non-invasive Vagus Nerve Stimulation (nVNS) for Treatment of Acute Stroke
February 09, 2022 08:00 ET
|
electroCore, Inc.
Clinical Trial (n=69) suggests safety and feasibility of nVNS for the acute treatment of stroke. Relative Ischemic Lesion Growth Decreased by 65.9% with nVNS vs. Sham Treatment. ROCKAWAY, N.J.,...
electroCore, Inc. Announces Completion of Enrollment in the TRANSIT Study of non-Invasive Vagus Nerve Stimulation (nVNS) in Post-Operative Ileus
February 01, 2022 08:00 ET
|
electroCore, Inc.
ROCKAWAY, N.J., Feb. 01, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced enrollment has been completed for the TRANSIT...
electroCore, Inc. Announces Three Abstracts to be Presented at International Stroke Conference 2022
January 25, 2022 08:00 ET
|
electroCore, Inc.
ROCKAWAY, N.J., Jan. 25, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced three abstracts focusing on the possible...
gammaCore™ Non-Invasive Vagus Nerve Stimulation(nVNS) Receives Breakthrough Device Designation for Treatment of Posttraumatic Stress Disorder (PTSD)
January 12, 2022 08:00 ET
|
electroCore, Inc.
ROCKAWAY, N.J., Jan. 12, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that its gammaCore™ nVNS device has received...
electroCore, Inc. Broadens Patient Access to gammaCore with Launch of U.S. Telehealth Portal and Online Store
January 11, 2022 08:00 ET
|
electroCore, Inc.
ROCKAWAY, N.J., Jan. 11, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the launch of an e-commerce shop for patients...
electroCore Announces Publication of PREMIUM II Trial of gammaCore (Non-Invasive Vagus Nerve Stimulation; nVNS) for the Prevention of Migraine
January 10, 2022 16:01 ET
|
electroCore, Inc.
ROCKAWAY, N.J., Jan. 10, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a peer-reviewed paper,...
electroCore to Present at H.C. Wainwright BIOCONNECT Virtual Conference
January 04, 2022 08:00 ET
|
electroCore, Inc.
ROCKAWAY, NJ, Jan. 04, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its management team will...
electroCore, Inc. Provides Update on Global Distribution Partners
December 16, 2021 08:00 ET
|
electroCore, Inc.
ROCKAWAY, NJ, Dec. 16, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced it has entered into agreements...
electroCore, Inc. Announces The Launch of a New Online Shop in the United Kingdom
December 15, 2021 08:00 ET
|
electroCore, Inc.
ROCKAWAY, NJ, Dec. 15, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced the launch of an e-commerce...
electroCore, Inc. Provides Update on nVNS to Treat Post Traumatic Stress Disorder
December 14, 2021 08:00 ET
|
electroCore, Inc.
ROCKAWAY, NJ, Dec. 14, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today provided an update on the ongoing...